PDS Biotech Reports Breakthrough Phase 2 mCRC Results
Princeton, New Jersey, U.S. | April 15, 2026 PDS Biotechnology has announced the publication of positive interim Phase 2...
NCI
Advertisement
Senhwa’s CX-5461 Gains FDA IND Clearance and NCI Support to Advance in MYC-Driven Lymphoma
Senhwa Biosciences, Inc. (TPEx: 6492), a clinical-stage biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has...
Advertisement
